Evidence map›Paper›PMID 42508420›Full record

ArticlePediatric pulmonology2026

Population Pharmacokinetic and Exposure-Response Analysis of Vancomycin Nephrotoxicity in Cystic Fibrosis Patients.

Jessica Barry, J G C van Hasselt, Michael Evans, Elizabeth B Hirsch, Jordan Dunitz, Sarah Shockley, Joanne Billings, Sílvia M Illamola

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric pulmonology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jessica BarryDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0002-4670-5650
J G C van HasseltLeiden University, Leiden, the Netherlands.ORCID https://orcid.org/0000-0002-1664-7314
Michael EvansClinical and Translational Science Institute, University of Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0001-7449-3993
Elizabeth B HirschDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0002-0462-0421
Jordan DunitzThe Minnesota Cystic Fibrosis Center, Department of Medicine, University of Minnesota School of Medicine, Minneapolis, Minnesota, USA.
Sarah ShockleyThe Minnesota Cystic Fibrosis Center, Department of Medicine, University of Minnesota School of Medicine, Minneapolis, Minnesota, USA.
Joanne BillingsDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Sílvia M IllamolaDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0003-3245-1626

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
Cystic Fibrosis Foundation ILLAMO20A0-INational Institutes of Health's National Center for Advancing Translational Sciences UL1TR002494NCATS NIH HHS UL1 TR002494
6 · The paper itself

Abstract

introductionAcute pulmonary exacerbations (APE) in persons with cystic fibrosis (PwCF) are associated with a reduction in long-term pulmonary function. Vancomycin is recommended as first-line treatment of methicillin-resistant Staphylococcus aureus -APE in PwCF. While vancomycin poses a significant risk of nephrotoxicity, the relationship between vancomycin exposure and nephrotoxicity in PwCF has not been characterized.

aimsWe aimed to establish the relationship between vancomycin exposure and onset of nephrotoxicity in PwCF, and to identify predictors of nephrotoxicity.

methodsThis was a retrospective study among 52 adults PwCF. Nephrotoxicity events were defined based on the RIFLE criteria, as a serum creatinine increase of 1.5 times from baseline or a ≥ 25% decrease in glomerular filtration rate. A population pharmacokinetic (popPK) model was used to derive exposure measures (i.e., area-under the concentration-time curve (AUC)).

resultsA total of 590 vancomycin serum concentrations were available for analysis. A one-compartment model best describes vancomycin pharmacokinetics. Creatinine clearance was included as a significant covariate in the clearance. The popPK model allowed quantification of cumulative AUC (AUC DISCUSSION: Our results demonstrate an association between increased vancomycin exposures and risk of nephrotoxicity. This study provides a foundation for optimizing personalized vancomycin dosing strategies in PwCF to balance efficacy and nephrotoxicity risk.

Indexed as

Anti-Bacterial AgentsCystic FibrosisKidney DiseasesStaphylococcal InfectionsVancomycinAdolescentAdultArea Under CurveCreatinineFemaleGlomerular Filtration RateHumansMaleMethicillin-Resistant Staphylococcus aureusRetrospective StudiesYoung AdultAnti-Bacterial AgentsCreatinineVancomycincystic fibrosisnephrotoxicitypharmacodynamicspopulation pharmacokineticsvancomycin

Identifiers

PMID42508420
PMCPMC13406165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.